Another limitation of the study was the scarcity of fine-grain characterization of FTLD and other non-Alzheimer’s tauopathies, and therefore we could not study the unique contribution of these tau subtypes to hippocampal atrophy. This evidence concerns the gene MAPT and hippocampal atrophy.